Duration of catalepsy correlates with increased intrastriatal sulpiride

European Journal of Pharmacology

Volumn 326, Issue 1, 1997, Pages 15-21

  Horikawa, Hiroshi P M ^a,b   Nakazato, Taizo ^b   Hikosaka, Okihide ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Behavior; Dopamine; Dopamine D2 receptor antagonist; Rat; Striatum; Voltammetry, in vivo

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG MONITORING; HISTOLOGY; INTRACEREBRAL DRUG ADMINISTRATION; NONHUMAN; POTENTIOMETRY; PRIORITY JOURNAL; RAT; TECHNIQUE;

1-METHYL-4-PHENYLPYRIDINIUM; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CATALEPSY; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; ELECTROCHEMISTRY; HOMOVANILLIC ACID; MALE; MICROINJECTIONS; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SULPIRIDE; TIME FACTORS;

EID: 0031011145     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00140-4     Document Type: Article

References (26)

1. Björklund, A., Lindvall, O., 1984. Dopamine-containing systems in the CNS. In: Björklund, A., Hökfelt, T. (Eds.), Handbook of Chemical Neuroanatomy, Vol. 2.: Classical Transmitters in the CNS, Part 1. Elsevier, Amsterdam, pp. 55-122.
2. Bradbury, A.J., Costall, B., Domeney, A.M., Jenner, P., Kelly, M.E., Marsden, C.D., Naylor, R.J., 1986. 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 319, 56-57.
3. Bressolle, F., Bres, J., Blanchin, M.D., Gomeni, R., 1984. Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. J. Pharm. Sci. 73, 1128-1136.
4. Brown, G.L., Linnoila, M.I., 1990. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J. Clin. Psychiatry 51, 31-41.
5. Bunney, W.E. Jr., Davis, J.M., 1965. Norepinephrine in depressive reactions. Arch. Gen. Psychiatry 13, 483-494.
6. Cass, W.A., Zahniser, N.R., Flach, K.A., Gerhardt, G.A., 1993. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61, 2269-2278.
7. Davis, K.L., Kahn, R.S., Ko, G., Davidson, M., 1991. Dopamine in schizophrenia: a review and reconceptuation. Am. J. Psychiatry 148, 1474-1486.
8. Fujiwara, H., 1992. Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice. Pharmacol. Biochem. Behav. 41, 301-308.
9. Heikkila, R.E., Manzino, L., Cabbat, F.S., Duvoisin, R.C., 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
10. Horikawa, H.P.M., Nakazato, T., Hikosaka, O., 1995. Close correlation between intrastriatal concentration of sulpiride and catalepsy as studied by in vivo voltammetry. Soc. Neurosci. Abstr. 21, 1132.
11. Horneykiewicz, O., 1966. Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. In: Costa, E., Côté, L.J., Yahr, M.D. (Eds.), Biochemistry and Pharmacology of the Basal Ganglia. Raven Press, New York, NY, pp. 171-185.
12. Imperato, A., Di Chiara, G., 1985. Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J. Neurosci. 5, 297-306.
13. Imperato, A., Di Chiara, G., 1988. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur. J. Pharmacol. 156, 385-393.
14. Kiyatkin, E.A., Stein, E.A., 1995. Fluctuation in nucleus accumbens dopamine during cocaine self-administration behavior: an in vivo electrochemical study. Neuroscience 64, 599-617.
15. Kiyatkin, E.A., Wise, R.A., Gratton, A., 1993. Drug and behavior-associated changes in dopamine-related electrochemical signals during intravenous heroin self-administration in rats. Synapse 14, 60-72.
16. Langston, J.W., Irwin, I., Langsten, E.B., 1984. Pargyline prevents MPTP-induced parkinsonism in primates. Science 225, 1480-1482.
17. Matsubara, S., Matsubara, R., Kusumi, I., Koyama, T., Yamashita, I., 1993. Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265, 498-508.
18. Nakazato, T., Akiyama, A., 1988. In vivo voltammetric study of 6-hydroxydopamine-induced neuronal degradation. J. Neurochem. 51, 1007-1013.
19. Nakazato, T., Akiyama, A., 1992. Decarboxilation of exogenous L-3,4-dihydroxyphenyl-alanine in rat striatum as studied by in vivo voltammetry. J. Neurochem. 58, 121-127.
20. + by in vivo voltammetry. Soc. Neurosci. Abstr. 19, 407.
21. Ossowska, K., Karcz-Kubicha, M., Wardas, J., Krezolek, A., Wolfarth, S., 1993. Zona incerta-lateral hypothalamus as an output structure for impulses involved in neuroleptic drug-induced catalepsy. Naunyn-Schmiedeberg's Arch. Pharmacol. 347, 415-420.
22. Seeman, P., 1992. Elevated D-2 in schizophrenia: role of endogenous dopamine and cerebellum. Neuropsychopharmacology 7, 55-57.
23. Shimada, S., Kitayama, S., Lin, C.L., Patal, A., Nanthakumar, E., Gregor, P., Kuhar, M., Uhl, G., 1991. Cloning and expression of a cocainesensitive dopamine transporter complementary DNA. Science 254, 576-578.
24. 3H]WIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats. J. Neurochem. 60, 469-476.
25. Wilson, J.M., Nobrega, J.N., Corrigall, W.A., Coen, K.M., Shannak, K., Kish, S.J., 1994. Amygdala dopamine levels are markedly elevated after self- but not passive-administration of cocaine. Brain Res. 668, 39-45.
26. Zetterström, T., Sharp, T., Ungerstedt, U., 1984. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur. J. Pharmacol. 106, 27-37.